Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Kairos Pharma, LTD. (KAPA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer LOS ANGELES — October 6, 2026 — Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressin
How this was made
The 30-second read
Why it matters
The interim efficacy data provides a tangible milestone that could de‑risk the program and attract partnership or licensing interest.
Market read
First disclosure of significant Phase 2 data; likely to move KAPA stock and influence biotech sector sentiment.
What to watch
Regulatory timeline, competition from other prostate‑cancer agents, and the need for Phase 3 data.
Background
Kairos Pharma (NYSE American: KAPA) is a clinical‑stage company developing ENV‑105, a CD105 antibody, for drug‑resistant cancers.
Ticker impact
Kairos Pharma disclosed statistically significant interim Phase 2 data showing median PFS of 17.7 months vs 2 months for control.
upward pressure as the market incorporates the strong efficacy signal
Phase 2 interim results with a p‑value of 0.0008 are material for a clinical‑stage biotech and often trigger price rallies.
Market effects
May boost sentiment for oncology biotech peers and increase interest in CD105‑targeted therapies.
Limited to U.S. and global biotech markets; no broader macro effect.
Relevant to investors tracking clinical‑stage biotech pipelines worldwide.
Counterpoint
If later data fails to confirm the interim signal, the stock could face a sharp correction.
Key entities
- CompanyKairos Pharma Ltd.
Clinical‑stage biopharma developing ENV‑105.
- ExecutiveDr. John Yu
CEO of Kairos Pharma, quoted on the trial results.
